Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Purchased by US Bancorp DE

0
75
Revance Therapeutics logo


US Bancorp DE boosted its holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) by 1,895.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 16,999 shares of the biopharmaceutical company’s stock after buying an additional 16,147 shares during the period. US Bancorp DE’s holdings in Revance Therapeutics were worth $458,000 at the end of the most recent reporting period.

→ Defy New Year Volatility with Artificial Intelligence (From Vantage Point)pixel

Other hedge funds have also recently added to or reduced their stakes in the company. Advisor Group Holdings Inc. raised its holdings in shares of Revance Therapeutics by 60.6% in the 1st quarter. Advisor Group Holdings Inc. now owns 2,838 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 1,071 shares during the period. Point72 Hong Kong Ltd purchased a new position in shares of Revance Therapeutics in the 2nd quarter worth about $92,000. Corton Capital Inc. purchased a new position in shares of Revance Therapeutics in the 2nd quarter worth about $162,000. Sciencast Management LP purchased a new position in shares of Revance Therapeutics in the 2nd quarter worth about $165,000. Finally, DCF Advisers LLC purchased a new position in shares of Revance Therapeutics in the 2nd quarter worth about $166,000. 82.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on RVNC shares. StockNews.com downgraded Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 13th. Guggenheim raised their target price on Revance Therapeutics to $36.00 in a report on Tuesday, November 15th. Morgan Stanley dropped their target price on Revance Therapeutics from $27.00 to $25.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 9th. Barclays raised their target price on Revance Therapeutics from $35.00 to $37.00 and gave the company an “overweight” rating in a report on Wednesday, November 16th. Finally, Needham & Company LLC raised their target price on Revance Therapeutics from $35.00 to $38.00 and gave the company a “buy” rating in a report on Tuesday, January 10th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Revance Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $38.20.

Revance Therapeutics Price Performance

Shares of NASDAQ RVNC opened at $31.70 on Monday. Revance Therapeutics, Inc. has a fifty-two week low of $11.27 and a fifty-two week high of $31.92. The business has a 50 day moving average price of $22.52 and a two-hundred day moving average price of $22.11. The company has a quick ratio of 5.33, a current ratio of 5.56 and a debt-to-equity ratio of 2.60. The firm has a market cap of $2.61 billion, a PE ratio of -8.09 and a beta of 0.57.

Revance Therapeutics (NASDAQ:RVNC – Get Rating) last issued its quarterly earnings data on Tuesday, November 8th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.32). Revance Therapeutics had a negative net margin of 251.92% and a negative return on equity of 461.54%. The business had revenue of $29.02 million for the quarter, compared to analyst estimates of $28.76 million. Sell-side analysts expect that Revance Therapeutics, Inc. will post -4.32 earnings per share for the current fiscal year.

Insider Transactions at Revance Therapeutics

In other news, CFO Tobin Schilke sold 3,701 shares of Revance Therapeutics stock in a transaction that occurred on Monday, January 9th. The stock was sold at an average price of $27.16, for a total value of $100,519.16. Following the completion of the transaction, the chief financial officer now owns 58,877 shares in the company, valued at approximately $1,599,099.32. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 5.10% of the company’s stock.

About Revance Therapeutics

(Get Rating)

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.

Read More

Institutional Ownership by Quarter for Revance Therapeutics (NASDAQ:RVNC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Revance Therapeutics, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Revance Therapeutics wasn’t on the list.

While Revance Therapeutics currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover



Source link